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Abstract 
Background: Behavioral and emotional adverse events induced by drugs commonly prescribed to patients with 
bipolar disorders are of paramount importance to clinical practice and research. However, no reviews on the topic 
have been published so far.
Methods: An extensive search was performed. Reports were reviewed if they described behavioral side effects 
related to pharmacological treatments for bipolar disorders in healthy subjects or patients with different neuropsy‑
chiatric disorders. For this review, lithium, antipsychotics, anticonvulsants and selective serotonin reuptake inhibitors 
were included.
Results: Apathy or emotional blunting, diminished sexual desire, and inability to cry were reported to be associated 
with exposure to selective serotonin reuptake inhibitors. Neuroleptic‑induced deficit syndrome/emotional detach‑
ment and obsessive–compulsive symptomatology and decision‑making modifications. A lithium‑related amotiva‑
tional syndrome was also reported in the literature. Furthermore, hypersexuality and obsessive–compulsive symp‑
toms have been noted in subjects treated with lamotrigine.
Limitations: Primary studies on drug‑related adverse events are scant so far and most of the data currently available 
derive from case reports. Moreover, most of the evidence reviewed is based on studies performed on healthy subjects 
and patients with neuropsychiatric conditions other than bipolar disorders.
Discussion: There is a remarkable dearth of data on behavioral adverse events of pharmacological treatment for 
bipolar disorders. However, the pieces of evidence available at present, though scant and scattered, suggest that dif‑
ferent behavioral adverse events may be related to pharmacological treatment for these disorders. The implications of 
these findings for research and management of patients with mood disorders are discussed.
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Background
Behavioral adverse events (BAEs) induced by pharmaco-
logical treatment are defined as symptoms referable to 
the central nervous system that produce a characteristic 
pattern of change in behavior and/or emotional response 
that is temporally related to the administration of a given 
drug, which exerts its effect alone or in combination with 
other drugs (Gates 2000). These symptoms can involve 
emotional, social, hedonistic, and/or sexual features and 
range from changes in normal behavior, such as sexual 
interest, to the emergence of complex behavior as, for 
example, pathological gambling. BAEs can be considered 
as unwanted events, but also as part of the therapeutic 
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effect of drugs in some cases. A proper knowledge of 
BAEs is indispensable to achieve an adequate manage-
ment of psychiatric conditions. Some BAEs are strong 
predictors of treatment adherence and can sometimes be 
quite similar to illness symptomatology, causing, due to 
these overlaps, problems in diagnosis and clinical assess-
ment (Awad et  al. 1996). Furthermore, studying BAEs 
may provide a pathway into the physiology of both nor-
mal and abnormal behavior, and into the mechanism of 
action of psychotropic drugs (Strejilevich et al. 2012).
Despite the clinical and theoretical relevance of BAEs, 
research and evidence-based descriptions on these topics 
are scarce and their consideration in clinical practice is 
almost null. Antipsychotic-related BAEs are an excellent 
way to describe this circumstance. Actually, the seren-
dipitous discovery of antipsychotics was due to the initial 
description of the BAEs produced by these drugs. Labo-
rit and Huguenard (1951) as well as Delay and colleagues 
(Delay et  al. 1952) began to experimentally use chlor-
promazine (the former as a pre-anesthetic and the latter 
as treatment for psychotic agitation) when they heard of 
a substance that produced affective indifference and lack 
of initiative both in experimental animals and in healthy 
volunteers. The term “neuroleptics” was then coined to 
name these drugs, underlining their ability to produce 
psychomotor retardation, affective indifference, and 
lack of initiative, which were considered their primary 
mechanisms of action (Deniker 1983; López-Muñoz et al. 
2005a, b). However, concomitantly to the expanding use 
of neuroleptics, physicians began to set aside this way to 
understand their clinical effects at the same time that the 
term “antipsychotic” was gradually extended as a way to 
name these drugs (King and Voruganti 2002). Around 
the 1970s, the interest in neuroleptic BAEs reemerged. 
In a series of original investigations, van Putten and 
colleagues showed that both motor and BAEs of antip-
sychotics helped to explain why many patients were 
reluctant to take these drugs and developed useful tools 
for early detection of patients who would not be adher-
ent to treatment (Van Putten 1974, 1975; Van Putten and 
May 1978; Van Putten et al. 1981). However, these con-
cepts were never fully incorporated into clinical practice 
or research.
In the 1990s, when atypical antipsychotics were 
launched onto the market, antipsychotic BAEs gained 
new attention (Voruganti et  al. 1999; Naber et  al. 2001; 
Chue 2006; Nasrallah and Lasser 2006). Newer termi-
nology and tools for assessment began to appear, and an 
association between these BAEs and D2 and D1 receptor 
occupancy was described, which was made possible by 
neuroimaging techniques (Lewander 1994; Naber 1995; 
De Haan et al. 2004, 2005; Lataster et al. 2011; Takeuchi 
et  al. 2013). Lastly, fifty years after the discovery of 
antipsychotics, the capacity of these compounds to pro-
duce affective indifference regained a central position in 
a model proposed by Kapur (2003), in which the effects 
of these drugs at the behavioral and cellular levels were 
integrated in a solid framework for the first time. This 
model returns over the observations of the pioneers in 
the use of antipsychotics, proposing that these drugs do 
not extinguish psychotic symptoms, but rather, they pro-
duce emotional detachment due to down-regulation of 
dopamine turn-over. It also assumes that apathy and lack 
of initiative is an unwanted consequence of the same psy-
chological mechanism that relieves psychotic symptoms 
(Kapur et al. 2006). However, leaving aside the progress 
and setbacks of research on antipsychotics, the underes-
timation of such secondary events has remained constant 
in both research and clinical settings.
Remarkably, although bipolar disorders (BDs) are more 
prevalent than schizophrenia and their treatment usu-
ally involves a larger variety of psychotropic drugs, no 
reviews of BAEs in the treatment of these disorders have 
been published. The aim of this work is to provide an 
updated overview of BAEs associated with those drugs 
more frequently used in the treatment of BDs and to 
discuss clinical and theoretical implications of research 
findings.
Methods
For the purpose or the current review, reports document-
ing the presence of BAEs in neuropsychiatric disorders or 
healthy control subjects were considered. We took into 
consideration only those drugs recommended as main 
treatment options for BDs by current clinical guide-
lines (Grunze et  al. 2013; Yatham et  al. 2013). Online 
databases (MEDLINE, SCOPUS, EMBASE and Clini-
calTrials.gov) were searched using the following terms: 
“SSRIs” or “MOOD STABILIZERS” or “ANTICONVUL-
SIVANTS” or “LITHIUM” or “ANTIPSYCHOTICS” or 
“NEUROLEPTICS” cross referenced with “SAFETY” or 
“TOLERABILITY” or “SIDE/ADVERSE EFFECTS” or 
“BEHAVIOR” or “CONDUCT.” We restricted our search 
parameters to reports published in English or Spanish up 
to August 2015. The reference lists of the articles selected 
for inclusion were also searched for relevant reports. 
With the objective to put focus on behavioral side effects, 
information on neurocognitive (attention, memory, pro-
cessing speed, etc.), motor (akathisia, parkinsonism, etc.), 
and autonomic (erectile dysfunction, ejaculatory delay, 
anorgasmia, etc.) adverse events was excluded. Nei-
ther were considered side effects on vigilance and appe-
tite regulation. In addition, since it is not clear whether 
switch to mania or impulsivity due to SSRI treatment 
is a behavioral adverse event or a modification in the 
course of illness, information on this issue was excluded. 
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Likewise, symptoms related to the underlying neuropsy-
chiatric condition (irritability, lethargy or fatigue) were 
excluded. Finally, we did not review reports on patients 
with mental retardation since this population may be 
unable to express discomfort from adverse events except 
by a change in their behavior (Gates 2000). After identi-
fying the most prevalent BAEs for each drug, data were 
summarized in a narrative fashion.
Results
A summary of the evidence for BAE induced by the main 
pharmacological treatments for BDs is presented in 
Table 1.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Four BAEs associated with SSRIs use were identified: 
apathy or emotional blunting, inability to cry, diminished 
sexual desire, and decision-making modifications.
Apathy or emotional blunting
Since the launch of SSRIs, evidence about behavioral 
changes exceeding the therapeutic effect of these drugs 
began to appear. In a book regarded as the landmark 
work about antidepressants, Kramer (1993) reported 
behavioral and personality changes in patients treated 
with fluoxetine. Although some of these changes may 
be accounted for by hypomanic symptoms, others can 
clearly be regarded as apathy or emotional blunting 
induced by this SSRI. From then on, data from different 
sources have documented the capacity of these drugs 
to ‘attenuate’ or ‘set aside everyday concerns,’ beyond 
their effect on depressive symptoms. A phenomenologi-
cal description of this BAE was provided by a qualitative 
study based on semi-structured individual interviews 
performed to 38 patients treated with SSRIs due to 
depressive or anxiety disorders (Price et  al. 2009). This 
investigation found that subjects experienced varying 
degrees of emotional detachment, which ranged from 
feeling as ‘just not caring’ about things previously consid-
ered as important to complete emotional numbing. Some 
participants felt like ‘covering up’ who they really were 
and reported financial and working problems because of 
‘just not caring.’ This detachment was experienced as a 
beneficial effect by some patients, but others experience 
it as a decrease in normal emotional responsiveness.
The frequency of apathy/emotional blunting occur-
rence during treatment with SSRIs has not been con-
sistently established. Reports vary widely, ranging from 
20 (Bolling and Kohlenberg 2004) to 80  % of patients 
receiving these antidepressants (Opbroek et  al. 2002). 
Apathy-emotional blunting could appear independently 
of the condition for which the SSRI is prescribed (major 
depressive disorder or anxiety disorders) (Barnhart et al. 
2004) and has been found in young adults and adoles-
cents (Hoehn-Saric et al. 1990, 1991; George and Trimble 
1992), older adults (Wongpakaran et al. 2007), and pedi-
atric population (Garland and Baerg 2001; Reinblatt and 
Riddle 2006) with depression or anxiety disorders. Emo-
tional blunting during treatment with SSRIs in unipo-
lar depression might be independent of the therapeutic 
effect of these drugs and could appear even after remis-
sion is achieved (Fava et al. 2006; Popovic et al. 2015).
Although relatively little or no research on the func-
tional impact of apathy-emotional blunting has been con-
ducted so far, some reports suggest that the emergence of 
this BAE could have a negative impact on normal func-
tioning (Barnhart et  al. 2004; Price et  al. 2009; Padala 
et al. 2012; Rothschild et al. 2014).
Clinical studies have brought support to the specificity 
of SSRIs to cause apathy-emotional blunting (Wongpa-
karan et  al. 2007; Di Giannantonio and Martinotti 2012) 
and, more specifically, to the association between these 
BAEs and 5HT2C agonism (Gobert et  al. 2002; Arnone 
et  al. 2009; Harmer et  al. 2011). SSRI-induced apathy 
does not revert after treatment with a noradrenergic and 
serotoninergic reuptake inhibitor (Raskin et al. 2012). The 
chronic elevation of serotonin levels in the nucleus accum-
bens leads, due to 5HT2C agonism, to a down-regulation 
of dopamine turn-over in circuits consistently associated 
with apathy or emotional blunting (Levy and Dubois 2006; 
Stahl 2013). A series of studies using emotional cognition 
paradigms have shown that SSRI antidepressants produce 
changes in emotional processing modifying the recogni-
tion of all basic emotions such as happiness, sadness, fear, 
disgust, and surprise (Browning et al. 2007; Harmer et al. 
2003, 2004, 2008, 2011) in healthy volunteers and depres-
sive subjects (Harmer et al. 2009). In contrast, other anti-
depressants with a different mechanism of action such as 
reboxetine (Harmer et al. 2004), mirtazapine (Arnone et al. 
2009; Rawlings et al. 2010) or agomelatine (Harmer et al. 
2011) may modify the processing of happiness and sad-
ness not modifying other basic emotions. In a recent study 
performed on 45 healthy volunteers, citalopram dimin-
ished neural processing of both rewarding and aversive 
stimuli while reboxetine did not suppress activity following 
reward stimuli and only mildly suppressed activity during 
the aversive conditions (McCabe et al. 2010).
Findings in BDs: Although this BAE has been studied in 
depression, we have not found data from patients with 
BDs.
Inability to cry
SSRI treatment has been associated with inability to cry 
in situations that would normally elicit crying (Oleshan-
sky and Labbate 1996; Opbroek et  al. 2002). Although 
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this event was considered as part of the SSRI-related 
emotional blunting/apathy complex, evidence from a 
case report of seven patients on SSRIs presenting with 
sudden inability to cry but without concomitant apathy 
criteria suggested that these BAEs might be independent 
(Holguin-Lew and Bell 2013).
Findings in BDs: we have not found data from patients 
with BDs.
Diminished sexual desire
SSRI-induced sexual dysfunction includes modifications 
in every stage of normal sexual functioning. The preva-
lence of this BAE was estimated around 20–45 %, being 
diminished libido the most frequent event (Aursnes and 
Gjertsen 2008; Clayton et  al. 2002). Sexual dysfunction 
might be present independently of the condition for 
which these drugs are prescribed (Montejo et al. 2001).
SSRI antidepressants diminish sexual interest, while 
those compounds with noradrenergic and dopaminergic 
reuptake inhibitor properties lack this effect (Serretti and 
Chiesa 2009; Clayton and Montejo 2006). SSRI-induced 
diminished libido does not revert after the addition of a 
noradrenergic reuptake inhibitor while it does after the 
addition of a dopaminergic and noradrenergic agents 
like mirtazapine, bupropion, or agomelatine (Gitlin et al. 
2002; Kennedy et  al. 2008; Atmaca et  al. 2011; Dueñas 
et al. 2011). This suggests that SSRIs cause this effect by 
impairing normal dopaminergic transmission, which is 
physiologically connected with the emotional blunting 
mechanism (Bijlsma et al. 2014). In this line, it has been 
proposed that diminished libido induced by SSRIs may 
be a sexual concomitant of emotional blunting. Indeed, 
Opbroek et al. (2002) found that 80 % of a sample of 15 
patients treated with SSRIs experienced diminished 
libido and also met criteria for apathy, inability to cry, 
and diminished creativity. None of the patients had sig-
nificant depressive symptomatology at the time of the 
evaluation. Furthermore, there was no significant corre-
lation between emotional blunting scores and depressive 
scores measured with the HAMD scale.
Findings in BDs: we have not found data from patients 
with BDs.
Decision‑making modifications
Although some ecological studies and subjective reports 
were published on possible changes or difficulties in 
decision-making processes in persons treated with SSRI 
(Kramer 1993; Price et  al. 2009; Molero et  al. 2015), 
research on this topic is scarce. In a recent study (Macov-
eanu et al. 2014), 29 healthy volunteers were exposed to 
40  mg fluoxetine for three weeks finding a significant 
reduction in neural responses to risky choices in orbito-
frontal cortex during a gambling task. The authors sug-
gested that these changes in decision-making might 
be pathophysiologically related to emotional blunting 
processes. The functional impact of this possible BAE 
remains understudied, although some authors have 
related changes in risk-taking with the increase in vio-
lence, crimes and self-injuries reported in young patients 
treated with SSRIs and other related antidepressants 
(Molero et al. 2015; Miller et al. 2014).
Serotonin has long been implicated in decision-mak-
ing processes. It has been suggested that serotonin is 
involved in processing and avoiding negative outcomes 
(Rogers et al. 2003; Tanaka et al. 2009), predicting future 
punishment (Crockett et  al. 2012), and loss aversion 
(Cools et  al. 2008). A significant reduction in the prob-
ability to choose the most likely outcome and a switch 
toward making the risky choice was found in healthy 
volunteers exposed to serotonin depletion (Rogers et al. 
1999; Long et al. 2009).
Findings in BDs: we have not found data from patients 
with BDs.
Antipsychotics (APs)
Different BAEs due to APs were found and subsumed, for 
the purposes of their description, into three subgroups: 
neuroleptic-induced deficit syndrome/emotional detach-
ment; obsessive–compulsive symptomatology; and deci-
sion-making modifications.
Neuroleptic‑induced deficit syndrome (NIDS)/emotional 
detachment
Many studies performed on healthy volunteers and clini-
cal populations show that exposure to APs produces a 
syndrome of dysphoria-apathy-apragmatism and loss of 
creativity. This syndrome has received different names 
(“neuroleptic dysphoria,” “akinetic depression,” “neurolep-
tic-induced deficit syndrome”, among others).
A variety of phenomenological descriptions of this syn-
drome are available, including systematic descriptions 
(Lewander 1994; Awad et  al. 1996), self-reports from 
patients (Moncrieff et  al. 2009) and healthy volunteers 
studies (de Haan et  al. 2005) even of psychiatrists who 
voluntarily exposed themselves to these drugs (Belmaker 
and Wald 1977). The behavioral and emotional adverse 
effects of APs would be different depending on whether 
the exposure to these drugs is acute or chronic. In acute 
exposure, psychomotor retardation, profound inner rest-
lessness and functional impairment due to a “paralysis 
of volition in absence of sedation,” has been frequently 
described. On the other hand, chronic exposure would 
produce a syndrome commonly known as NIDS, which 
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includes apathy-emotional detachment, lack of energy, 
dysphoria, reduced drive and initiative and loss of crea-
tivity among its symptoms (Lewander 1994).
The incidence of these BAEs has not been established. 
However, the close relationship between the emotional 
detachment produced by APs and their therapeutic effect 
(Kapur et al. 2005) suggests that these BAEs could always 
be present, with different intensity and functional impact. 
Both NIDS and emotional detachment reports are also 
extended to second-generation APs (de Haan et al. 2000, 
2003; Lataster et al. 2011; Takeuchi et al. 2013). Although 
NIDS/emotional detachment has been related to extrapy-
ramidal side effects (Gervin et  al. 1999; de Haan et  al. 
2003; Kim and Byun 2010), it could emerge before motor 
symptoms appear (de Haan et al. 2000). These BAEs have 
been strongly correlated with functional impairments 
and lack of compliance (Awad et al. 1996; de Haan et al. 
2004; Fischel et al. 2013) with treatment, both with first- 
and second-generation APs (Lambert et  al. 2003; Awad 
and Voruganti 2004). In the last years, imaging tech-
niques studies have strongly correlated this BAE with the 
percentage of D2 occupancy (de Haan et al. 2000, 2003).
Findings in BDs: Although this BAE has been extensively 
studied in schizophrenia, there are virtually no data 
from patients with BDs. Recently, Moncrieff et al. (2009) 
published an analysis of comments posted by users in 
an Internet site (http://www.askapatient.com) regard-
ing their subjective experiences with treatment drugs. 
The authors found that both older and new APs were 
especially linked to emotional effects, which included 
feelings of flattened or numbed emotions, loss of inter-
est and motivation, reduced creativity, and perceived 
changes in personality. Interestingly, 33.6 % of the reports 
came from self-defined bipolar patients and 11.7 % from 
depressive patients. However, as this website recorded 
opinions from users of these drugs, respondents may 
have misinterpreted the origin of their symptoms and 
reported them as produced by the drug and not by their 
underlying condition.
Obsessive–compulsive symptomatology (OCS)
Findings from retrospective (Mahendran et al. 2007) and 
prospective (Schirmbeck et al. 2013) cohort studies sug-
gest a causal relationship between OCS and treatment 
with second-generation antipsychotics (SGA), particu-
larly clozapine. Furthermore, a dose–response pattern 
(Lin et al. 2006; Schirmbeck et al. 2011) and an associa-
tion between duration of treatment and OCS severity 
have been reported in SGA-treated schizophrenic sub-
jects (Schirmbeck et  al. 2011). Among these patients, 
the prevalence of OCS was found to be of 28.4  % (Lin 
et al. 2006). Atypical APs have a preferential occupancy 
of 5HT2 receptors over D2 (Kapur et  al. 1998, 1999, 
2006) being this profile of antiserotoninergic proper-
ties thought to be the cause of OCS induction (Schirm-
beck et al. 2011; 2013; Schirmbeck and Zink 20122013). 
Recent studies suggest that OCD and OCS are associated 
with greater suicidal risk in patients with schizophrenia 
(Niendam et al. 2009; DeVylder et al. 2012; Hagen et al. 
2013; Szmulewicz et  al. 2015a), underlining the impor-
tance of this BAE.
Findings in BDs: a case report of two bipolar type I 
patients treated with clozapine documented the devel-
opment of OCS (Lemke and Bustillo 2013). In another 
case report, three bipolar type I patients treated with 
high doses of quetiapine also presented with OCS as a 
side effect (Stamouli and Lykouras 2006). Similarly, Jonk-
ers and de Haan (2002) reported OCS induction due to 
olanzapine treatment in a BD type II patient. No studies 
evaluating the functional impact or effects on suicidality 
of this BAE in BDs patients have been published so far.
Decision‑making modifications
A recent review on decision-making process in schizo-
phrenia (Adida et  al. 2011) found conflicting results. 
While some studies presented impaired performance 
on decision-making tests, others did not. Authors stated 
that a major source of uncontrolled bias was the relation-
ship between AP medication and decision-making per-
formance. For example, neither dosages of APs nor the 
relationship between performance and percentage of D2 
occupancy is recorded in most studies. Current hypoth-
eses state that impairment on decision-making tasks in 
schizophrenia are related to a biased sensitivity to punish-
ment, which may be due to a motivational deficit as well 
as an abnormal risk perception (Hutton et al. 2002; Pren-
tice et al. 2005; Heerey et al. 2008; Trémeau et al. 2008). 
To what extent this may be caused by pathophysiological 
processes due to the illness itself or to adverse events due 
to AP treatment is yet to be determined. In line with this, 
there are some reports of healthy subjects underperform-
ing on the Iowa Gambling Task (IGT) following a sudden 
dopamine reduction (Sevy et al. 2006; Vrshek-Schallhorn 
et  al. 2013). However, it must be noted that one study 
assessing IGT performance in de-novo drug-naïve Parkin-
son’s disease patients (Poletti et al. 2011) found no differ-
ences between patients and controls.
Findings in BDs: No data regarding this issue in BDs 
patients were found.
Lithium
Data from healthy volunteers and case reports have 
shown that lithium could produce an amotivational 
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syndrome related to its plasma levels. Early studies con-
ducted on healthy volunteers (Schou 1968; Bonetti et al. 
1977; Judd et al. 1977; Belmaker et al. 1979; White et al. 
1979; Kropf and Muller-Oerlinghausen 1979) found an 
amotivational syndrome induced by this drug. They also 
showed that this syndrome had a dose–response pattern, 
being more prominent in patients with higher lithium 
serum levels.
Some studies investigated this syndrome in patients 
with BDs (Bonetti et al. 1977; White et al. 1979; Kropf 
and Müller-Oerlinghausen 1975; Folstein et  al., 1982) 
finding similar results as in healthy volunteers. Kropf 
and Müller-Oerlinghausen (1975) conducted a double-
blind study on 14 euthymic lithium-treated patients. 
In one group, subjects maintained their usual blood 
levels, whereas in the other, subjects had a dose reduc-
tion. The results showed that patients with high lithium 
blood levels were less active and less expansive, how-
ever, 29 % of the reduced-blood level group experienced 
an affective recurrence during follow-up. Whether this 
syndrome is produced as a side effect of lithium therapy 
or as consequence of mood stabilization is a matter of 
controversies. Folstein et  al. (1982) compared a group 
of euthymic BD patients on chronic lithium therapy 
with normal control subjects using the Visual Analogue 
Mood Scale for 30  days to evaluate mood variability. 
They found that patients’ mood was less variable than 
that of the control group. The authors attributed this 
unusual degree of mood stability to the effects of lith-
ium treatment and suggested that euthymic patients 




OCS induced by lamotrigine has been described in epi-
leptic (Lombroso 1999; Verma et al. 1999; Lee et al. 2011) 
and schizophrenic patients (Szmulewicz et  al. 2015b). 
These symptoms appear to be dose-related (over 100 mg/
day are described in the above reports) and revers-
ible after treatment discontinuation. Lamotrigine would 
increase dopamine levels in cortico-striato-thalamo-cor-
tical circuits due to glutamate agonism. This effect would 
be related to both OCS generation and beneficial out-
comes for behavior and cognition (Pittenger et al. 2011). 
Finally, there are two case reports of lamotrigine induc-
tion of hypersexuality (Grabowska-Grzyb et  al. 2006) in 
epileptic patients.
Findings in BDs: OCD and tic disorders due to lamo-
trigine exposure have also been reported in BD patients 
(Seemüller et al. 2006; Alkin et al. 2007; Kemp et al. 2007; 
Kuloglu et al. 2009) (Table 1).
Valproic acid (VA)
There are few reports on BAE in patients treated with VA 
in epileptic population and most of them report unspe-
cific effects (Marson et al. 2007; Shehata et al. 2009).
Findings in BDs: No studies assessing the impact of these 
effects on BD patients have been performed.
Discussion
This review shows the existence of a remarkable knowl-
edge gap on behavioral and emotional side effects of 
drugs commonly used in the treatment of BD, both in 
clinical practice and in research. Indeed, the main limita-
tion of this work concerns the lack of systematicity, which 
is explained, at least partly, by the non-existence of valid 
instruments and methodology to assess adverse events 
and also by the lack of previous reviews on this topic. 
However, this shortcoming does not imply an absence of 
evidence. Despite being scant and scattered, the available 
data are consistent, showing that many commonly used 
drugs would have the potential to produce behavioral 
and emotional side effects with clinical and theoretical 
implications. For example, although lithium and lamo-
trigine are usually seen as “psychologically clean” drugs, 
both could produce BAEs. Available studies suggest that 
lithium may produce an amotivational syndrome—which 
would be dose dependent—and lamotrigine could pro-
duce obsessive–compulsive symptoms. In both cases, 
incidence and functional impact of these BAEs have not 
been determined and are currently not included in clini-
cal guidelines.
On the other hand, despite the fact that significant 
amounts of data provide insights about the capacity of 
SSRIs to produce BAEs due to modifications in emotional 
processing in healthy volunteers and unipolar depression 
patients, there are no data for BD patients. Moreover, this 
lack of information extends even to unipolar depression 
patients, for which, in the same way, data about how apa-
thy/emotional-blunting impact on overall outcome and 
functionality are hardly available.
However, negligence of BAEs is especially impressive 
in the case of the use of APs in BDs patients. Although 
an increasing number of people affected by these disor-
ders are being treated with these kinds of drugs (Pillarella 
et al. 2012; Mauer et al. 2014), the lessons learned from 
schizophrenia about antipsychotic-related BAEs do not 
seem to have influenced this clinical field. As shown in 
this review, there are no studies exploring the subjective 
and behavioral impact of these drugs and their possible 
therapeutic and functional consequences on patients 
with BDs. Nor have there been any studies including 
instruments specifically designed to explore possible 
BAEs in the many recent trials of APs done on BDs.
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Indeed, the frequency and potential impact of the BAEs 
extensively described in schizophrenia remain uncer-
tain in BD patients. Nevertheless, there are no reasons 
to expect the absence of such side effects in BDs. If we 
take into account that NIDS and neuroleptic dysphoria 
have been consistently related to motor side effects in 
schizophrenic patients (Awad et  al. 1996; Gervin et  al. 
1999; de Haan et al. 2003; Kim and Byun 2010), then we 
should expect a higher vulnerability to these BAEs in BD 
patients due to their comparatively higher sensitivity to 
extrapyramidal side effects of APs (Gao et al. 2008).
It is clear that the described situation represents an 
information vacuum with respect to the data that clini-
cians and patients need to make their therapeutic deci-
sions rationally. Even today, the BAEs here described are 
not included in the sources of information on adverse 
effects most commonly used (i.e., Epocrates©). Further-
more, in order to identify some BAEs, it is particularly 
necessary that patients know about their potential exist-
ence in order to become aware that they may suffer them. 
Due to its phenomenological characteristics, a side effect 
like apathy may go unnoticed even for the person who is 
experiencing it. Likewise, the fact that some drugs com-
monly used to treat BDs might produce biases or distor-
tions in the decision-making process takes the problem 
to another level. This is an unexplored field, for which the 
development of new ways to observe and measure BAEs 
is needed in order to make these potential effects accessi-
ble in such a way that they can be discussed by clinicians 
and users.
The findings discussed here have clear implications for 
the design of research on the efficacy of pharmacologi-
cal treatments for BDs and even for mood disorders in 
general. It is clear that actions to control these side effects 
should be routinely taken in clinical trials, especially in 
the case of those drugs that can cause apathy/emotional 
flattening. Apathy and emotional blunting have a sig-
nificant overlap with depressive symptoms in the instru-
ments usually used (Marin et  al. 1993). Consequently, 
the presence of these side effects can decrease the scores 
on depression scales and hide the presence of this new 
symptomatology at the same time. On the other hand, 
although limited, the available data suggest that BAE 
produced by drugs usually indicated in BDs treatment 
could produce a significant impact on the functionality 
and clinical outcome of affected subjects. It is possible to 
speculate that the functional impact attributed to BAE 
could be involved in the dissociation between syndromic 
and functional recovery frequently observed in treat-
ments of these disorders.
Finally, although many different medications have 
shown efficacy in delaying or avoiding new affective 
crises, there is no framework able to explain the exist-
ent hiatus between the biochemical changes produced by 
these drugs and their effects at the behavioral level. Many 
new questions and ways to investigate could be addressed 
if BAEs were considered, as has been the case in schizo-
phrenia (Kapur 2003). For example, BAEs of these drugs 
could help to explore whether the mechanisms by which 
lithium, some antipsychotics, and some anticonvul-
sants prevent mood episodes are similar or not. In the 
same way, the consideration of these issues could help 
to formulate an integrative pathophysiology of BDs. For 
instance, similarities between neuroleptic-induced dys-
phoria and dopamine withdrawal syndromes, and agi-
tated depression have led to propose a model to explain 
mixed states in BDs (Strejilevich et al. 2012).
In conclusion, drug-related BAEs have relevant impli-
cations for both clinical and research practice. It is urgent 
to address this issue, thus solving an ethical problem 
and certainly leading to an increase in the quality and 
quantity of information on BAEs. However, most of the 
available evidence in the literature is just descriptive. 
Therefore, there is an urgent need for developing ques-
tionnaires or scales specifically designed to measure this 
aspect of pharmacological treatment in mood disorders 
and BDs in particular. Furthermore, given that we are far 
from having a complete understanding of the pharmaco-
dynamics of the treatments that we daily use, disregard-
ing BAEs in research hypotheses is simply leaving aside a 
rich source of information.
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